THE COST-EFFECTIVENESS OF HERCEPTIN IN ADJUVANT SETTING- THE HERA TRIAL
Author(s)
Neyt M1, Cocquyt V2, Albrecht J11 Ghent University, Gent, Belgium; 2 University Hospital Gent, Gent, Belgium
Presentation Documents
OBJECTIVES: Trastuzumab as adjuvant therapy is being tested in a number of large randomised trials. Our purpose is to calculate the cost implications of using trastuzumab as in the HerA trial and provide information on the product's value for money. METHODS: Standard breast-cancer treatment models were set up for different subpopulations according to stage (I, II, III) and menopausal condition (
Conference/Value in Health Info
2005-05, ISPOR 2005, Washington, DC, USA
Value in Health, Vol. 8, No. 3 (May/June 2005)
Code
PCN9
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology